Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination

References

• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400 - 4; http://dx.doi.org/10.1038/nature10755; PMID: 22318521
   PubMed Web of Science ®Google Scholar
• DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405 - 9; http://dx.doi.org/10.1038/nature10803; PMID: 22318517
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235 - 71; http://dx.doi.org/10.1146/annurev-immunol-031210-101324; PMID: 21219185
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775 - 87; http://dx.doi.org/10.1016/j.cell.2008.05.009; PMID: 18510923
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A 2003; 100:10902 - 6; http://dx.doi.org/10.1073/pnas.1834479100; PMID: 12947044
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, et al. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 2005; 201:681 - 6; http://dx.doi.org/10.1084/jem.20041959; PMID: 15753203
   PubMed Web of Science ®Google Scholar
• Hindley JP, Ferreira C, Jones E, Lauder SN, Ladell K, Wynn KK, et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011; 71:736 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-10-1797; PMID: 21156649
   PubMed Web of Science ®Google Scholar
• Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628 - 36; http://dx.doi.org/10.1182/blood-2005-07-2737; PMID: 16179369
   PubMed Web of Science ®Google Scholar
• Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007; 178:2155 - 62; PMID: 17277120
   PubMed Web of Science ®Google Scholar
• Bilate AM, Lafaille JJ. Induced CD4(+)Foxp3(+) Regulatory T Cells in Immune Tolerance. Annu Rev Immunol 2011; PMID: 22224762
   PubMed Web of Science ®Google Scholar
• Adeegbe D, Matsutani T, Yang J, Altman NH, Malek TR. CD4(+) CD25(+) Foxp3(+) T regulatory cells with limited TCR diversity in control of autoimmunity. J Immunol 2010; 184:56 - 66; http://dx.doi.org/10.4049/jimmunol.0902379; PMID: 19949075
   PubMed Web of Science ®Google Scholar
• Pannetier C, Cochet M, Darche S, Casrouge A, Zöller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A 1993; 90:4319 - 23; http://dx.doi.org/10.1073/pnas.90.9.4319; PMID: 8483950
   PubMed Web of Science ®Google Scholar
• Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998; 4:215 - 21; http://dx.doi.org/10.1038/nm0298-215; PMID: 9461196
   PubMed Web of Science ®Google Scholar
• Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114:4099 - 107; http://dx.doi.org/10.1182/blood-2009-04-217604; PMID: 19706884
   PubMed Web of Science ®Google Scholar
• Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM. Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol 2008; 181:8209 - 13; PMID: 19050237
   PubMed Web of Science ®Google Scholar
• Selvaraj RK, Geiger TL. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 2008; 180:2830 - 8; PMID: 18292504
   PubMed Web of Science ®Google Scholar
• Zhang H, Podojil JR, Chang J, Luo X, Miller SD. TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol 2010; 184:6629 - 36; http://dx.doi.org/10.4049/jimmunol.0904044; PMID: 20483764
   PubMed Web of Science ®Google Scholar
• Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol 2007; 178:4022 - 6; PMID: 17371955
   PubMed Web of Science ®Google Scholar
• Hänig J, Lutz MB. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J Immunol 2008; 180:1405 - 13; PMID: 18209035
   PubMed Web of Science ®Google Scholar
• Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172:4676 - 80; PMID: 15067041
   PubMed Web of Science ®Google Scholar
• Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 2011; 35:109 - 22; http://dx.doi.org/10.1016/j.immuni.2011.03.029; PMID: 21723159
   PubMed Web of Science ®Google Scholar
• Huter EN, Punkosdy GA, Glass DD, Cheng LI, Ward JM, Shevach EM. TGF-beta-induced Foxp3+ regulatory T cells rescue scurfy mice. Eur J Immunol 2008; 38:1814 - 21; http://dx.doi.org/10.1002/eji.200838346; PMID: 18546144
   PubMed Web of Science ®Google Scholar
• Davidson TS, Shevach EM. Polyclonal Treg cells modulate T effector cell trafficking. Eur J Immunol 2011; 41:2862 - 70; http://dx.doi.org/10.1002/eji.201141503; PMID: 21728170
   PubMed Web of Science ®Google Scholar
• DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007; 179:4685 - 93; PMID: 17878367
   PubMed Web of Science ®Google Scholar
• Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol 2008; 181:1798 - 805; PMID: 18641317
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012; 482:395 - 9; http://dx.doi.org/10.1038/nature10772; PMID: 22318520
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125 - 38; http://dx.doi.org/10.1084/jem.20080099; PMID: 18725522
   PubMed Web of Science ®Google Scholar
• Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636 - 45; http://dx.doi.org/10.1016/j.immuni.2009.04.010; PMID: 19464986
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A 2005; 102:5126 - 31; http://dx.doi.org/10.1073/pnas.0501701102; PMID: 15795373
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329 - 41; http://dx.doi.org/10.1016/j.immuni.2005.01.016; PMID: 15780990
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330 - 6; http://dx.doi.org/10.1038/ni904; PMID: 12612578
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556 - 61; http://dx.doi.org/10.1073/pnas.95.13.7556; PMID: 9636188
   PubMed Web of Science ®Google Scholar
• Fang L, Adkins B, Deyev V, Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med 2008; 205:1037 - 48; http://dx.doi.org/10.1084/jem.20072528; PMID: 18411341
   PubMed Web of Science ®Google Scholar
• Matsutani T, Ohmori T, Ogata M, Soga H, Kasahara S, Yoshioka T, et al. Comparison of CDR3 length among thymocyte subpopulations: impacts of MHC and BV segment on the CDR3 shortening. Mol Immunol 2007; 44:2378 - 87; http://dx.doi.org/10.1016/j.molimm.2006.10.026; PMID: 17156844
   PubMed Web of Science ®Google Scholar